
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is projected to experience substantial revenue growth, with an anticipated increase of over 20% annually through 2026, driven by commercial sales of established products and recent launches. The company's total income from royalty agreements surged to $28.5 million in 2024, a significant rise from $4.8 million in 2023, indicating robust growth in its royalty-based income streams. Continued expansion of its royalty aggregate business and the potential contributions from earlier-stage assets, including milestone payments, further support a positive financial outlook for XOMA.
Bears say
XOMA Royalty Corp has experienced significant volatility in its revenues and net earnings, primarily due to the unpredictable nature of the international biotech market, suggesting an inherent sensitivity to economic fluctuations and policy changes. The company faces challenges such as potential setbacks in clinical trials and funding shortages, which could severely hinder its ability to progress drug candidates and adversely impact operational sustainability. Additionally, recent stock performance indicates a decline from pandemic-era highs, exacerbated by broader market downturns in the biotechnology sector, raising concerns about investor confidence and long-term growth prospects.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares